Related references
Note: Only part of the references are listed.Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers
SeungHwan Lee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients
Peter F. Troke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation
Steven M. Trifilio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes
Kazuaki Matsumoto et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders
Koki Ueda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Hallucinations during voriconazole therapy
Dimitrios I. Zonios et al.
CLINICAL INFECTIOUS DISEASES (2008)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2008)
Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2008)
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms
Mark-David Levin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
Steve Trifilio et al.
CANCER (2007)
Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections
Jan G. den Hollander et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Voriconazole therapeutic drug monitoring
J Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Pharmacokinetic/pharmacodynamic profile of voriconazole
Ursula Theuretzbacher et al.
CLINICAL PHARMACOKINETICS (2006)
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
S Trifilio et al.
BONE MARROW TRANSPLANTATION (2005)
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration
TJ Walsh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus
S Ascioglu et al.
CLINICAL INFECTIOUS DISEASES (2002)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
DW Denning et al.
CLINICAL INFECTIOUS DISEASES (2002)
Share Paper
